Innovent Confirms Lilly Collaboration Effective, Denies Acquisition Rumors

Innovent Biologics ( (HK:1801) ) has shared an update.

Innovent Biologics has confirmed that its previously announced strategic collaboration agreement with Eli Lilly to advance novel oncology and immunology medicines has become effective as of March 24, 2026, after receiving early clearance from the U.S. Federal Trade Commission. The effectiveness of this partnership is expected to support Innovent’s pipeline development and reinforce its positioning in cutting-edge therapeutic areas, although the company advises investors to exercise caution when dealing in its securities.

The company also issued a clarification addressing media reports that mischaracterized the Lilly collaboration as an acquisition of Innovent, stating unequivocally that no such transaction is underway or planned. Management urged shareholders and potential investors not to rely on market rumors and to base any decisions solely on official company announcements, seeking to stabilize market expectations and limit speculation around its strategic direction.

The most recent analyst rating on (HK:1801) stock is a Buy with a HK$115.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.

More about Innovent Biologics

Innovent Biologics, Inc. is a biopharmaceutical company focused on developing and commercializing novel medicines, particularly in oncology and immunology. Listed in Hong Kong, the group operates through subsidiaries to advance innovative therapies for patients in China and globally, often via strategic collaborations with multinational pharmaceutical partners.

Average Trading Volume: 11,109,293

Technical Sentiment Signal: Buy

Current Market Cap: HK$134.5B

Find detailed analytics on 1801 stock on TipRanks’ Stock Analysis page.